Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17116617 | 0.86 | CYP11B2 (0.62) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL2983844 | 0.84 | CYP11B2 (0.61) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL17116594 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL21044264 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL6085958 | 0.81 | CYP11B2 (0.66) | CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL12947990 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL30725703 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL17116450 | 0.81 | CYP11B2 (0.61) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL1651440 | 0.81 | CYP11B2 (0.56) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL2979806 | 0.81 | CYP11B2 (0.56) | CYP11B2CYP11B1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108976212-A | Fluorene derivative and its application in luminous organic material | 北京鼎材科技有限公司 | 2018-12-11 | — | — | CN | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| EP-2166015-A1 | LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | CYP11B2 1407/4885CYP11B1 886/4885MAP4K4 2183/4885 |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | SIRT6, LAS1L, MRPS18A | CYP11B2 3827/4885CYP11B1 3818/4885MAP4K4 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.